Microzide

Quick links to important sections

Microzide

Method of action: Diuretic

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Microzide

Property Description
Active ingredient Hydrochlorothiazide (HCTZ)
Form Oral capsule, Oral tablet
Pharmacological class Thiazide Diuretic
General purpose Fluid volume reduction and blood pressure management
Origin Synthetic, Sulfonamide derivative

What Type of Medicine is Microzide?

Microzide is the trade name for a prescription-only medication whose active pharmaceutical ingredient is Hydrochlorothiazide (HCTZ). This drug is classified pharmacologically as a thiazide diuretic, a specific type of diuretic that is chemically identified as a sulfonamide derivative. As a foundational antihypertensive agent, its primary purpose is managing fluid volume and blood pressure. Thiazide diuretics are clinically recognized for effective long-term management of hypertension, supporting the medicine’s recognized role in cardiovascular health.


Composition, Origin, and Form of Microzide

The medication's effect stems entirely from its single active ingredient, Hydrochlorothiazide. Microzide is typically formulated as an oral capsule, but the underlying HCTZ substance is widely available as an oral tablet for ingestion via the oral route. It is a single-ingredient product, containing HCTZ combined with standard solid oral preparation excipients. The sulfonamide structure of HCTZ is a key pharmacological feature, distinguishing its mechanism of action from other diuretic types.


What is the General Purpose of Microzide?

Microzide’s general purpose is to promote the renal excretion of excess salt (sodium) and water, thereby causing diuresis and a controlled reduction in fluid volume. It achieves this by inhibiting the reabsorption of sodium and chloride in the kidney tubules. This sustained fluid reduction is why Microzide is generally used to help manage persistent high blood pressure and alleviate symptoms associated with fluid retention or edema. A typical neutral use scenario involves managing blood pressure in adult patients who require a mild, sustained diuretic effect.

Regulatory References

  1. Thiazide Diuretics - StatPearls - NCBI Bookshelf

What side effects are possible with Microzide?

Possible Side Effects and Safety Information

The official safety profile for Hydrochlorothiazide, the active ingredient in Microzide, is primarily defined by its effects on metabolism and electrolyte balance. These are the most common adverse reactions documented by regulatory authorities, including Hypokalemia (low potassium), Hyperglycemia (elevated blood sugar), and Hyperuricemia.


System-Organ Classifications and Frequencies

Side effects are officially classified into System-Organ Classes (SOCs), which include Metabolism and Nutrition Disorders, Gastrointestinal Disorders (e.g., nausea, vomiting, constipation), and Nervous System Disorders (e.g., dizziness, headache).

Classification Examples of Reactions
Common Hypokalemia, Hyperglycemia, Dizziness
Rare Pancreatitis, Jaundice, Photosensitivity
Very Rare Agranulocytosis, Toxic Epidermal Necrolysis (TEN)
Frequency Not Known Acute Myopia, Secondary Angle-Closure Glaucoma

Serious Adverse Reactions and Restrictions

Official labels highlight rare but serious adverse reactions, notably Acute Myopia and Secondary Angle-Closure Glaucoma, which can occur within hours to weeks of starting the medicine. Severe blood disorders, such as Aplastic Anemia, are also documented.

Regulatory safety statements specify constraints for specific populations. The drug is contraindicated in patients with Anuria (lack of urine production) or known sulfonamide hypersensitivity. Caution is required in patients with pre-existing renal or hepatic impairment, as the drug may increase the risk of conditions like hepatic coma or azotemia. Additionally, an increased risk of Non-Melanoma Skin Cancer has been noted with long-term exposure, correlating with cumulative dose.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Microzide (Hydrochlorothiazide) is primarily characterized by the exaggerated effects of diuresis, resulting in severe fluid and electrolyte depletion. Regulatory documents state that this overexposure can lead to serious physiological abnormalities, including Hypotension (low blood pressure), Tachycardia (fast heart rate), and Oliguria (reduced urine output). Clinical signs of severe depletion include profound weakness, lethargy, confusion, and muscle cramps. Gastrointestinal disturbances such as nausea and vomiting are also documented manifestations.

A critical risk associated with overdosage is the potential for life-threatening complications. Severe loss of electrolytes, particularly potassium (Hypokalemia), may provoke cardiac arrhythmia (abnormal heart rhythm) or increase the heart's sensitivity to other medications. Additionally, the official labeling warns of the risk of seizures and life-threatening dilutional hyponatremia. Patients with pre-existing impaired renal function may risk developing azotemia, and those with severe liver disease may face the risk of precipitating hepatic coma.

In the event of suspected overdosage, the required action is to seek immediate medical attention or call emergency services. Regulatory guidance emphasizes that no specific pharmacological antidote is known. Management is strictly symptomatic and supportive, focused on the rapid correction of severe fluid volume deficits and electrolyte imbalances, which includes monitoring serum electrolytes.

Therapeutic Uses of Microzide

Microzide is a medication used to assist in the management of specific health conditions by promoting the removal of excess water and salt from the body. This therapeutic action helps to support healthy fluid balance and is a component of a comprehensive care strategy. It is commonly prescribed to help individuals manage high blood pressure (hypertension) and to address fluid retention (edema) linked to conditions such as congestive heart failure, severe liver conditions, or various forms of kidney dysfunction.

This medicine aids in lessening the physical discomfort and symptoms associated with fluid accumulation. The accepted clinical scenarios for this treatment include chronic stable hypertension and fluid-related swelling.

Quick Fact: Relief for Fluid-Related Swelling Microzide supports the body’s ability to excrete surplus fluid, which can contribute to the relief of symptoms like swelling and heaviness in affected limbs.

Eligibility and Restrictions for Use

Microzide (hydrochlorothiazide) eligibility is strictly defined by regulatory guidelines based on a patient’s medical status, age, and physiological condition.

Eligibility and Exclusion Status

Category Official Regulatory Classification Status
Anuria (No urine production) Contraindicated Must Not Use
Sulfonamide Allergy Contraindicated Must Not Use
Adults (18+ years) Approved Can Use
Pediatric Patients Safety and effectiveness Not Established Not Recommended
Lactation (Breastfeeding) Not Recommended (Decision to discontinue nursing or the drug required) Restricted Use

Condition-Based Eligibility Restrictions

Use of Microzide requires caution in patients with certain pre-existing medical conditions, as specified in regulatory labeling:

  • Severe Renal Impairment: Not recommended if creatinine clearance is less than 30 mL/min. The drug may precipitate azotemia (buildup of waste products in the blood).
  • Impaired Hepatic Function: Use with caution, as fluid changes may precipitate hepatic coma in severe liver disease.
  • Systemic Lupus Erythematosus (SLE): Use with caution due to the risk of exacerbation or activation of the condition.
  • Acute Myopia / Secondary Angle-Closure Glaucoma: The drug must be discontinued immediately upon the acute onset of these vision changes.

Older adults may also require caution due to potential increased sensitivity and age-related changes in organ function. Pregnancy use is not routinely recommended and is permitted only if clearly needed, as the drug crosses the placental barrier.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hydrochlorothiazide, the active ingredient in Microzide, has documented interaction patterns based on official regulatory labeling. These interactions are classified by their pharmacokinetic, pharmacodynamic, or risk-based outcomes.


Interaction Scope

Classification Official Regulatory Documentation
Medicinal product categories with documented interactions Other Antihypertensive Drugs, Antidiabetic Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Narcotics, Nondepolarizing Skeletal Muscle Relaxants.
Specific interacting medicines (if explicitly listed) Aliskiren, Lithium, Cholestyramine, Colestipol.
Interaction-related restrictions Co-administration with Aliskiren is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment.

Resulting Interaction Structure

Official regulatory documents define the product’s interaction profile primarily through pharmacokinetic effects on absorption and clearance, and pharmacodynamic effects on blood pressure and electrolytes.

  • Lithium clearance is reduced when co-administered with Microzide, which results in increased serum concentrations of Lithium and a high risk of toxicity.
  • The absorption of Hydrochlorothiazide is significantly reduced by Cholestyramine and Colestipol resins; a separation of administration is required to mitigate this effect.
  • Alcohol, barbiturates, or narcotics can have an additive effect that increases the risk and severity of orthostatic hypotension.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the diuretic, natriuretic, and blood pressure lowering effects of Hydrochlorothiazide.
  • Co-administration with Corticosteroids or ACTH leads to intensified electrolyte depletion, particularly the risk of hypokalemia.

Mechanism of Action

Targeted Inhibition of Salt and Water Reabsorption

This mechanism involves the drug acting as a specific inhibitor of the Sodium-Chloride Cotransporter (NCC), a membrane protein located in the Distal Convoluted Tubule of the kidney . By blocking this reabsorption process, the drug prevents the body from reclaiming sodium and chloride ions, thereby creating an osmotic gradient that traps water within the kidney tubule. This initial action initiates increased excretion of water and salt, leading to a net decrease in plasma volume.


Modulation of Vascular Tone and Systemic Resistance

Beyond the acute fluid shift, the drug's mechanism includes a distinct sustained, volume-independent change in the circulatory system. This involves modulating the function of arterial smooth muscle cells, likely through influencing local ion channels, which leads to a gradual reduction in Total Peripheral Vascular Resistance (TPR). The sustained vascular change contributes significantly to the full expression of the drug's systemic mechanism, while also indirectly promoting a secondary mechanism of reduced excretion of calcium ions (Ca^2+) within the kidney tubules.

Dosage and Administration Information

Instruction Map: How to use Microzide — Administration Guidelines

This map formalizes the instructions for using Microzide (hydrochlorothiazide), focusing solely on procedural and dosing constraints.


Administration Scope

Feature Requirement
Route of administration Oral ingestion (tablet, capsule, or reconstituted suspension).
Adult Hypertension Dosing Initial dose is typically 12.5 mg to 25 mg once daily; maximum is 50 mg daily, given as a single or divided dose.
Adult Edema Dosing Initial and maintenance range is 25 mg to 100 mg daily, taken as a single or divided dose. Intermittent therapy (e.g., alternate days) may be used.
Timing in relation to food Administration of the Microzide capsule form results in reduced absorption when taken with food.
Preparation requirements The oral suspension must be reconstituted prior to dispensing by adding water, followed by vigorous shaking, and must be measured using an oral dosing syringe.
Age-group administration Use is not recommended in patients with severe renal impairment (creatinine clearance <30 mL/min); a lower starting dose (e.g., 12.5 mg) is often recommended for older adults.
Missed-dose rules If a dose is missed, it should be taken as soon as remembered, but the missed dose must be skipped if it is almost time for the next scheduled dose. Double doses are strictly forbidden.
Special procedural conditions Dosing is typically recommended in the morning to avoid nighttime urination (nocturia). The dose of other concurrent antihypertensive agents may need reduction.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Once daily, or divided/intermittent for edema
Use-context constraints Morning dosing, renal function limitations, and co-therapy adjustments

Connection to the Overall Use Protocol

The instructions establish a standardized protocol for use, mandating the oral route and a once-daily morning schedule for consistent action. This framework defines explicit initial and maximum adult dose ranges for both hypertension and fluid retention, while incorporating non-advisory constraints related to renal function, age, and co-administration with other agents.

Recent Clinical Evidence

Research evidence / Overview of studies for Microzide

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research exploring the use of Microzide (hydrochlorothiazide) for high blood pressure (hypertension) includes multiple large-scale studies, including several long-term Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies are recognized as Randomized Controlled Trials (RCTs). Trials primarily focused on adults with essential hypertension and examined treatment regimens using the drug both as a single agent and in combination with other blood pressure medicines. Researchers monitored a range of crucial outcomes monitoring physiological strain or stress, including blood pressure (BP) measurements and the long-term incidence of major cardiovascular events, such as stroke and heart attack, over extended periods.

Studies reported patterns observed in the trials regarding blood pressure measurements and the rates of serious cardiovascular outcomes in the groups studied. The data show patterns related to the use of the thiazide diuretic class, which Microzide belongs to, in the management of chronic hypertension. For patients with severely impaired kidney function, research suggests that the findings indicate a reduced effect on the expected outcomes related to systemic or functional imbalance (specifically, fluid and electrolyte effects), leading to uncertainty about its use in this subgroup.


Evidence for Use in Managing Fluid Retention (Edema)

Microzide was studied for its use as an adjunctive treatment for fluid retention (edema) associated with various health issues, as researched in populations with underlying heart, liver, or kidney dysfunction. This evidence base includes clinical trials that primarily focused on measuring outcomes related to physical discomfort, such as changes in the appearance of swelling, as well as objective measures like changes in body weight and urine output in the observed populations.

In these studies, research highlights changes measured during the study period in parameters related to fluid volume. Specifically, trials reported how symptoms evolved in the observed populations regarding the excretion of sodium and water. Follow-up durations were limited in many of the edema-focused studies compared to hypertension trials, meaning that long-term patient-reported outcomes describing perceived discomfort related to fluid balance are not always fully established. The results apply only to the populations studied.


The Landscape of Evidence Gaps and Uncertainties

Despite the large amount of research available, there are still areas where the data remain insufficient or where certainty remains low. Comparative evidence is lacking in some areas when comparing Microzide (HCTZ) directly to similar thiazide-class drugs over many years. Furthermore, subgroup findings are uncertain for individuals with the most severe forms of renal impairment. The research does not determine whether an individual will respond similarly to the group averages observed in the trials. Instead, evidence highlights what is known—and what is still uncertain—about this medicine's research base.

Frequently Asked Questions (FAQ)

Common questions about Microzide (FAQ)


Q: How quickly should I expect to see my blood pressure start to change after starting Microzide?

A: The initial effect of Microzide is typically diuresis, which is an increase in urine flow. Regulatory documents indicate this effect generally begins within 2 hours of taking a dose and lasts for 6 to 12 hours. The full blood pressure-lowering effect is typically seen after consistent, chronic use, as the initial fluid effects are followed by a gradual change in vascular resistance.


Q: Are there any dietary restrictions I need to know about while taking Microzide?

A: The official product information does not mandate specific, restrictive diets. However, general lifestyle advice often includes controlled sodium (salt) intake when managing high blood pressure. Given the risk of electrolyte changes, dietary considerations, particularly regarding potassium, are often a focus of treatment monitoring.


Q: How long does the effect of a single dose of Microzide last in the body?

A: Microzide's primary effect is time-limited. Official pharmacokinetic data indicates that the diuretic action, which is the increased urination, usually lasts between 6 to 12 hours after a single oral dose.


Q: Why do some people need to take potassium supplements with Microzide?

A: Microzide can cause Hypokalemia (low potassium levels) due to increased excretion of potassium in the urine. Official labeling notes that taking potassium supplements or consuming increased potassium-rich foods may be used to help prevent or manage this electrolyte imbalance.


Q: What are the signs that Microzide might be working for my condition?

A: For high blood pressure, the intended effect is a measurable reduction in blood pressure. If Microzide is being taken for fluid retention (edema), this includes increased urine output and reduced swelling, as described in studies.


Q: Can taking Microzide cause muscle cramps or weakness?

A: Yes, official safety information lists muscle pains, cramps, and muscular fatigue as potential warning signs. These symptoms are potential warning signs associated with fluid and electrolyte imbalances that can be caused by the medicine.


Q: Can Microzide affect my sleep or cause insomnia?

A: Restlessness is listed in adverse reaction data as a potential symptom related to fluid or electrolyte imbalance. This effect may be a factor affecting sleep, though specific sleep disorders are not typically listed.


Q: Is it safe to drink alcohol while being treated with Microzide?

A: Official warnings state that alcohol can have an additive effect with Microzide, potentially increasing the risk of orthostatic hypotension. Orthostatic hypotension is a sudden drop in blood pressure that can cause dizziness or fainting upon standing.


Q: Does Microzide have to be taken at a specific time of day?

A: Yes, regulatory recommendations suggest that dosing is typically done in the morning. This timing is intended to help prevent nocturia, which is the need to wake up and urinate during the night.


Q: What kind of monitoring (blood tests) is usually required while on Microzide?

A: Official guidelines emphasize that periodic blood tests are necessary to monitor safety. This monitoring includes the determination of serum electrolytes, such as potassium and sodium, to detect possible imbalances. Blood sugar levels are also monitored closely, particularly in diabetic patients.


Q: Can older adults safely take Microzide for hypertension?

A: Microzide is approved for use in adults, including older individuals. However, official labeling notes that a lower dose may be used for older adults, and caution is advised due to potential increased sensitivity.


Q: Does Microzide cause fatigue or tiredness in new users?

A: Official adverse reaction data includes weakness, lethargy, and drowsiness as potential symptoms. These are generally related to disturbances in fluid and electrolyte balance that the medicine can cause.


Q: Is it normal to feel a bit thirsty after starting Microzide?

A: Yes, regulatory precautions list dryness of mouth and increased thirst as potential warning signs. These are recognized symptoms that may indicate an emerging fluid or electrolyte imbalance.


Q: What research evidence supports the use of Microzide for heart health?

A: Research, including long-term clinical trials, establishes Microzide's effectiveness in managing chronic hypertension. The drug is associated with a reduction in the long-term risk of major cardiovascular events, such as stroke and heart attack, through blood pressure management.


Q: Can Microzide affect my cholesterol levels?

A: Official product information notes that Microzide can potentially cause an increase in serum levels of triglycerides and cholesterol. Specifically, changes in LDL and VLDL cholesterol levels have been noted in the product information.


Q: Is Microzide safe to take if I have a history of gout?

A: The drug is known to cause elevated uric acid (hyperuricemia), which is associated with gout. Since the drug can cause hyperuricemia, caution is generally indicated for individuals with pre-existing gout or a history of high uric acid levels.


Q: Does Microzide interact with heart rhythm medications?

A: Electrolyte imbalances such as low potassium and magnesium can be a factor affecting the heart. These imbalances can sensitize the heart to the toxic effects of certain heart medicines, such as digitalis, or can potentially be a factor in causing irregular heart rhythms.


Q: Can Microzide cause increased sensitivity to the sun?

A: Yes, official documents list photosensitivity as a documented hypersensitivity reaction. This indicates that the drug may increase the skin's sensitivity to sunlight, raising the risk of sunburn.


Q: Is it true that Microzide can deplete magnesium levels?

A: Yes, official precautions state that patients should be monitored for signs of electrolyte disturbances, including hypomagnesemia, or low magnesium levels. This indicates that magnesium depletion is a known potential effect of the drug.


Q: Are there specific signs of dehydration to look for while on Microzide?

A: Official warnings describe signs of fluid and electrolyte imbalance, which may include dry mouth, thirst, weakness, lethargy, drowsiness, and muscle cramps. These are potential symptoms that should be monitored.


Q: Can Microzide be taken with food or on an empty stomach?

A: Official administration instructions indicate that taking the capsule form with food results in reduced absorption. The drug label emphasizes the importance of following the specific instructions provided by a healthcare professional regarding administration.


Q: Is Microzide approved for use in children?

A: Official regulatory documents state that the safety and effectiveness of Microzide have not been established in pediatric patients (children). Therefore, its use is generally not recommended in this population.


Q: Are there common skin reactions associated with Microzide?

A: Official adverse reaction data includes several skin-related issues. These documented reactions include photosensitivity, rash, urticaria (hives), and purpura (purple spots).


Q: Does Microzide interact with diabetes medications?

A: Yes, official precautions note that Microzide can potentially cause hyperglycemia, or high blood sugar. Because of this, diabetic patients may require an adjustment to their prescribed dose of insulin or other antidiabetic medications.


Q: Why do some doctors prescribe Microzide in combination with an ACE inhibitor?

A: This combination is often used in hypertension treatment because it uses two different mechanisms—diuresis (fluid reduction) from Microzide and vessel relaxation from the ACE inhibitor—to achieve a greater blood pressure effect.

How should Microzide be stored and disposed of?

Microzide (hydrochlorothiazide) must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).

Storage Conditions

  • The medication must be protected from light, moisture, and must not be frozen.
  • The container must be kept tightly closed to maintain product stability.
  • For child safety, Microzide must be stored in a secure location, out of the sight and reach of children.

Disposal Instructions

  • Unused or expired Microzide must be properly discarded.
  • Do not flush the medication down the toilet or pour it into a drain unless specific instructions from a regulatory authority permit this method.
  • Consult local guidelines or a pharmacist regarding proper disposal programs, such as medication take-back sites.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Microzide found in:

A-Z Index: